Related Experiment Videos

Nebivolol for the treatment of heart failure

Allison S Dery, Leslie A Hamilton, Jessica A Starr

    American Journal of Health-System Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
    |May 7, 2011
    PubMed

    Insights

    Nebivolol offers benefits for heart failure patients, improving ejection fraction and exercise capacity. However, its effectiveness may be less than other recommended beta-blockers, warranting further comparative studies.

    Area of Science:

    • Cardiology
    • Pharmacology
    • Clinical Trials

    Background:

    • Nebivolol is a third-generation, highly beta-1 selective beta-blocker used for hypertension.
    • It possesses unique peripheral vasodilatory action via nitric oxide enhancement.
    • Beta-blockers can slow heart failure progression by antagonizing adrenergic stimulation.

    Purpose of the Study:

    • To review the pharmacology, pharmacokinetics, efficacy, safety, and therapeutic role of nebivolol.
    • To evaluate nebivolol's effects in patients with chronic heart failure.

    Main Methods:

    • Review of existing literature on nebivolol.
    • Analysis of clinical trials comparing nebivolol (5-10 mg daily) with placebo and carvedilol in heart failure patients.
    • Assessment of the Study of the Effects of Nebivolol Intervention on Outcomes and Rehospitalisation in Seniors with Heart Failure (SENIORS).

    Main Results:

    • Nebivolol demonstrated improvements in left ventricular ejection fraction, volumes, and exercise capacity in heart failure.
    • The SENIORS trial showed reduced morbidity and mortality compared to placebo, though potentially less than other beta-blockers.
    • Common adverse events included bradycardia, hypotension, and dizziness; nebivolol was generally well tolerated.

    Conclusions:

    • Nebivolol exhibits beneficial effects in managing heart failure.
    • Its efficacy appears less pronounced than other currently recommended beta-blockers for heart failure.
    • Further large-scale comparative trials are needed to define nebivolol's definitive role in heart failure therapy.

    Related Concept Videos

    Heart Failure Drugs: β-Blockers01:22

    Heart Failure Drugs: β-Blockers

    β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
    Heart Failure Drugs: Inotropic Agents01:26

    Heart Failure Drugs: Inotropic Agents

    Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

    Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

    The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
    Heart Failure V: Medical Management01:30

    Heart Failure V: Medical Management

    Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
    Heart Failure VI: Adjunct Therapies01:22

    Heart Failure VI: Adjunct Therapies

    Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
    Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

    Adrenergic Antagonists: ɑ and β-Receptor Blockers

    Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...